Prestige Consumer Healthcare Q2 revenue beats on acquisition boost
Overview
US consumer healthcare firm's Q2 revenue rose 22.7%, beating analyst expectations
Adjusted diluted EPS for Q2 increased to $1.13 from $1.07 last year
Company cut fiscal 2027 revenue and EPS outlook due to Clear Eyes® supply issues
Outlook
Prestige Consumer Healthcare cuts FY27 revenue outlook to $1.28 bln-$1.29 bln
Company lowers FY27 adjusted diluted EPS forecast to $4.48-$4.55
Company expects Clear Eyes® supply constraints to weigh on second-half revenue
Result Drivers
ACQUISITIONS - Revenue growth driven by contributions from Breathe Right and LaCorium acquisitions in both North American and International segments
CLEAR EYES DECLINE - Organic revenue fell due to lower Clear Eyes sales and order timing headwinds
HYDRALYTE GROWTH - International segment benefited from double-digit sales growth for Hydralyte
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $336.31 mln | $329.13 mln (7 Analysts) |
Q2 Net Income | $25.30 mln | ||
Q2 Gross Profit | $172.54 mln | ||
Q2 Operating Expenses | $91.83 mln | ||
Q2 Operating Income | $80.71 mln | ||
Q2 Pretax Profit | $47.45 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc. is $69.50, about 30.4% above its November 4 closing price of $53.28
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 11 three months ago
Reuters Recommended Reads
Nov 4 - Evolus Q3 revenue rises 13% on toxin and HA gel growth
Nov 4 - CVS beats Q3 revenue, profit estimates, outlook raised; to split into two
Nov 2 - Tempus AI Q3 revenue slightly beats estimates; raises guidance
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)